Latest From Mirum Pharmaceuticals
The start-up run by ex-Lumena leadership is testing REN001 for rare genetic mitochondrial diseases with two Phase Ib trials under way and plans to start a third later this year.
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.
Part 1: Execs from rare disease-focused companies weighed in on investor sentiment during a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference.
A review of biopharma start-up dealmaking and financing activity from October through December 2018, based on data from Strategic Transactions.
- Specialty Pharmaceuticals
- Therapeutic Areas
- Hepatic (Liver)
- North America
- Company Type
- Parent & Subsidiaries
- Mirum Pharmaceuticals
- Senior Management
Chris Peetz, CEO
Pamela Vig, PhD, CSO
Lara Longpre, Chief Development Officer
- Contact Info
San Diego, CA
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.